June 29, 2022

Medical Trend

Medical News and Medical Resources

Aesthetic medicine: Botox is facing the strong challenge from Jeuveau?

Aesthetic medicine: Botox is facing the strong challenge from Jeuveau?



 

Aesthetic medicine: Botox is facing the strong challenge from Jeuveau?

 

According to the data, botulinum toxin is a class of neurotropic exotoxin produced by botulinum toxin under anaerobic conditions (10°C, anaerobic, suitable acidity).

There are eight types of botulinum toxin, A, B, Cα, Cβ, D, E, F, and G. Among them, type A botulinum toxin is the most potent and is currently the most widely used botulinum toxin.

In the field of medical beauty, everyone is familiar with the functions of “botulinum toxin”: muscle reduction, face and leg reduction, wrinkle removal , etc. Since these functions are in the urgent needs of beauty lovers, “botulinum toxin” has been used for many years. One of the most popular medical beauty products in the world.

 

Recently, the “botox” market in the United States has been revived, and Jeuveau, a rising star known as the “perfect alternative” of Botox®, is on the rise. 

 

On February 2, 2022, Abbvie Inc announced its 2021 annual financial report, in which Allergan Aesthetics’ Botox® ( Botox) for medical aesthetics generated revenue of US$2.232 billion ( unless otherwise specified). Remarks, the following performance information refers to medical beauty ).

 

[Note: In May 2020, AbbVie completed the acquisition of Allergan. Allergan’s medical aesthetics business was operated independently and renamed Allergan Aesthetics. The parent company is AbbVie. 】

 

Previously, from 2015 to 2020, the performance of Botox® were: US$860 million, US$1.21 billion, US$1.37 billion, US$1.55 billion, US$1.66 billion, and US$1.12 billion.

 

It can be seen that after a brief decline in performance in 2020, Botox® has achieved a relatively obvious rebound in 2021. However, as the top global leader in ” botulinum toxin”, Botox® is facing more challenges.

 

Rising stars in U.S. market

 

As can be seen from the latest financial report released by AbbVie, the market of Allergan Aesthetics is mainly divided into the US market and the global market (markets outside the US) .

Among them, the performance of Botox® in the US market in 2021 is US$142.4 million, and the performance of the global market is US$80.8 million. It can be seen that the market size of the US market is nearly twice that of the global market, and it is the main battlefield of Botox® .

 

Aesthetic medicine: Botox is facing the strong challenge from Jeuveau?

(Image source: AbbVie Annual Report)

 

In the United States, there are four main types of “botulinum toxin” approved by the FDA:

 

(1) Allergan Aesthetics – Botox®

 

In 1989, Botox® was first approved by the U.S. FDA for the treatment of blepharospasm and strabismus in adults. It is the world’s first approved botulinum toxin type A product .

 

In 2002, Botox® was first approved by the FDA for the temporary improvement of moderate-to-severe frown lines, as well as for the temporary improvement of moderate-to-severe crow’s feet and forehead lines in adults, with applications ranging from medical to cosmetic expand .

 

In the field of medical aesthetics, Botox® is the world’s first botulinum toxin product, and has maintained the first global market share in this field for many years , with the highest global share once reaching as high as 86%.

 

(2) Galderma – Dysport

 

It is reported that Lisuto ® has the advantage of diffusion. In the face of large-area treatment areas such as the calf and the shoulder trapezius , Lisuto® can spread slowly and evenly, so the effect is faster and better. It is usually used by consumers to thin legs and shoulders.

 

(3) Merz – Xeomin

 

It is reported that Xima® is the only “Oragnic” organic and natural version of botulinum toxin: because it contains any additives and protective proteins, there is only botulinum toxin type A. Often used by consumers to treat subtle facial wrinkles.

 

(4)Evolus——Jeuveau

 

According to the data , Jeuveau is the first FDA-approved “botulinum toxin” specially used for medical aesthetics , which is different from “Botox” such as Botox® , which has other medical effects in addition to medical aesthetics .

 

It is reported that Jeuveau is the most similar “botulinum toxin” to Botox® in composition , and some even call it the “perfect alternative” to Botox®.

 

It is worth mentioning that behind the closest relationship between Jeuveau and Botox® , there is a special grievance and hatred——

 

In January 2019, Allergan and Medytox sued Evolus, pointing out that Evolus used trade secrets provided by former Medytox employees to develop Jeuveau, of which Jeuveau and Botox use the same strain of botulinum, and that the research cost Allergan a lot of time and cost .

 

In December 2020, the U.S. International Trade Commission issued an order banning the import, sale and marketing of Jeuveau in the United States for up to 21 months.

 

In early 2021, AbbVie (already acquired by Allergan), Medytox and Evolus settled an intellectual property dispute over Jeuveau in a coordinated manner.

 

According to the agreement, AbbVie and Medytox allow Jeuveau to sell in its other jurisdictions in the United States, while Evolus must pay AbbVie and Medytox milestones and sales royalties for Jeuveau, and give Medytox approximately $6.76 million worth of common stock shares .

 

On March 5, 2022, Jeuveau’s 2021 results were released, with annual sales of $99.7 million, a year-on-year increase of 76%. It is reported that some Wall Street analysts believe that the drug has a lot of room for growth, and many people in the industry also believe that Jeuveau, as a rising star of Botox, is threatening.

 

 

Aesthetic medicine: Botox is facing the strong challenge from Jeuveau?

(source:internet, reference only)


Disclaimer of medicaltrend.org